CTSB and inflammatory bowel disease: Recent studies have confirmed that recombinant T. spiralis cysteine protease inhibitor relieved TNBS-induced experimental inflammatory bowel disease by inducing Th2-type immune response and balanced the Th1-type immune response induced by TNBS administration (Xu et al., 2019).